Serina Therapeutics (SER) director boosts equity via conversions and new warrants
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Serina Therapeutics director Gregory Bailey reported a series of stock acquisitions and conversions tied to prior financing agreements and equity awards. On June 17, 2026, 762,548 shares of Series A Convertible Preferred Stock were mandatorily converted into 1,755,555 shares of common stock, plus 15,250 additional shares issued as accrued dividends, after stockholders approved the conversion terms.
Separate transactions show common stock issued upon automatic conversion of Pre-Funded Warrants originally purchased at $2.2499 per warrant under a March 17, 2026 Securities Purchase Agreement, following stockholder approval obtained on June 17, 2026. Bailey also received 3,333,333 redeemable warrants with a $5.00 exercise price and 15,250 stock options with a $1.98 exercise price as additional derivative awards.
Positive
- None.
Negative
- None.
Insights
Transactions reflect conversions and awards rather than open‑market buying or selling.
Director Gregory Bailey increased his common stock exposure in Serina Therapeutics through mandatory conversion of Series A Convertible Preferred and automatic conversion of Pre-Funded Warrants after stockholder approval on June 17, 2026. These moves largely formalize equity from prior financings.
He also received 3,333,333 redeemable warrants with a $5.00 exercise price and 15,250 stock options at $1.98 per share. These are compensation- and financing-related instruments, not open-market trades, so they typically carry weaker signaling value than discretionary insider purchases or sales.
Footnotes describe conditions such as NYSE American stockholder-approval requirements and warrant call features tied to the SER-252 Phase 1b SAD study. Subsequent company filings may clarify how and when these derivatives are exercised or called.
Insider Trade Summary
762,548 shares exercised/converted
Mixed
5 txns
Insider
Bailey Gregory
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 15,250 | $0.00 | -- |
| Grant/Award | Redeemable Warrants | 3,333,333 | $0.00 | -- |
| Conversion | Series A Convertible Preferred Stock | 762,548 | $2.25 | $1.72M |
| Conversion | Common Stock | 1,770,805 | $2.25 | $3.98M |
| Conversion | Common Stock | 6,666,667 | $2.2499 | $15.00M |
Holdings After Transaction:
Stock Option (right to buy) — 15,250 shares (Direct, null);
Redeemable Warrants — 3,333,333 shares (Direct, null);
Series A Convertible Preferred Stock — 0 shares (Direct, null);
Common Stock — 1,897,445 shares (Direct, null)
Footnotes (1)
- Shares reflect the mandatory conversion at an adjusted Conversion Price of $2.25 of the Company's Series A Convertible Preferred Stock ("Series A Preferred") issued in connection with the April 2025 Private Placement. The Reporting Person was originally issued 762,548 shares of Series A Preferred that were converted into 1,755,555 shares of Common Stock and 15,250 shares that were issued for payment of accrued dividends. Shares were issued upon receipt of stockholder approval, which approval was obtained on June 17, 2026, and the underlying Common Stock shares were issued on June 17, 2026. The share ownership amount has been updated to reflect the correct number of shares beneficially owned by the Reporting Person. Issued pursuant to a Securities Purchase Agreement dated March 17, 2026, at a purchase price of $2.2499 per pre-funded warrant (reflecting a $0.0001 exercise price). The Pre-Funded Warrants have no expiration date and are subject to customary beneficial ownership limitations. The exercise price and share count are subject to adjustment for stock splits, dividends, and similar events. Under NYSE American rules, issuance of the underlying shares to the reporting person is subject to prior stockholder approval which was obtained on June 17, 2026, thereby triggering the automatic conversion of the Pre-Funded Warrants into common stock. The stock options will vest on the earlier of (i) the day before the next Annual Meeting or (ii) the one-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. Issued pursuant to the same Securities Purchase Agreement dated March 17, 2026, covering 50% of the shares underlying the Pre-Funded Warrants acquired by the reporting person. The Company may call the warrants at $0.01 per underlying share upon 30 days' notice if the Common Stock closing price equals or exceeds $10.00 on the business day prior to the redemption notice, on the earlier of (i) 30 days after first patient dosing in Cohort 2 of the Company's SER-252 Phase 1b SAD study or (ii) September 30, 2026. Holders have 30 days to exercise following a call notice. The Series A Convertible Preferred Stock is perpetual and therefore has no expiration date.
Key Figures
Series A preferred converted: 762,548 shares
Common shares from Series A: 1,755,555 shares
Redeemable warrants granted: 3,333,333 warrants
+4 more
7 metrics
Series A preferred converted
762,548 shares
Series A Convertible Preferred Stock mandatorily converted on June 17, 2026
Common shares from Series A
1,755,555 shares
Common stock issued upon Series A conversion plus 15,250 dividend shares
Redeemable warrants granted
3,333,333 warrants
Derivative grant with $5.00 exercise price, expiring March 17, 2030
Warrant exercise price
$5.00 per share
Exercise price for redeemable warrants on Serina common stock
Stock options granted
15,250 options
Right to buy common stock at $1.98, expiring June 17, 2036
Option exercise price
$1.98 per share
Exercise price for stock options granted June 17, 2026
Pre-Funded Warrant price
$2.2499 per warrant
Purchase price under March 17, 2026 Securities Purchase Agreement
Key Terms
Series A Convertible Preferred Stock, Pre-Funded Warrants, beneficial ownership limitations, Securities Purchase Agreement, +1 more
5 terms
Series A Convertible Preferred Stock financial
"Shares reflect the mandatory conversion at an adjusted Conversion Price of $2.25 of the Company's Series A Convertible Preferred Stock"
Series A convertible preferred stock is a class of shares sold in an early funding round that gives investors a mix of protection and upside: it pays a priority claim over common shares if the company is sold or closes, but can be converted into ordinary shares to share in future growth. Think of it like a hybrid between a safer stake and a ticket to ownership; it matters to investors because it affects who controls the company, how future gains are split, and how much their investment is protected from downside.
Pre-Funded Warrants financial
"Issued pursuant to a Securities Purchase Agreement dated March 17, 2026, at a purchase price of $2.2499 per pre-funded warrant"
Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.
beneficial ownership limitations financial
"The Pre-Funded Warrants have no expiration date and are subject to customary beneficial ownership limitations."
Beneficial ownership limitations are rules or contractual caps that restrict how much of a company’s stock an individual or entity can be treated as owning or controlling for legal, regulatory or corporate-governance purposes. They matter to investors because such limits affect voting power, reporting obligations, takeover risk and the ability to increase a stake — like an elevator weight limit or a lane divider that prevents any one car from taking over the whole road.
Securities Purchase Agreement financial
"Issued pursuant to a Securities Purchase Agreement dated March 17, 2026, at a purchase price of $2.2499 per pre-funded warrant"
A securities purchase agreement is a written contract between a buyer and a seller outlining the terms for buying or selling financial assets such as stocks or bonds. It specifies details like the price, quantity, and conditions of the transaction, similar to a shopping list with agreed-upon terms. For investors, it provides clarity and legal protection when transferring ownership of these financial instruments.
Phase 1b SAD study medical
"on the earlier of (i) 30 days after first patient dosing in Cohort 2 of the Company's SER-252 Phase 1b SAD study or (ii) September 30, 2026."
FAQ
What did Serina Therapeutics (SER) director Gregory Bailey report on this Form 4?
Gregory Bailey reported acquiring Serina Therapeutics common stock through conversions and equity awards. Mandatory conversion of Series A preferred and automatic conversion of Pre-Funded Warrants increased his common stock exposure, alongside new redeemable warrants and stock options granted on June 17, 2026.
What are the key terms of the redeemable warrants reported for Serina Therapeutics (SER)?
Bailey received 3,333,333 redeemable warrants, each exercisable for one Serina Therapeutics common share at an exercise price of $5.00. The company may call these warrants at $0.01 per share if share-price and clinical milestones or a September 30, 2026 date condition are met.
What stock options were granted to Gregory Bailey by Serina Therapeutics (SER)?
Bailey was granted 15,250 stock options to buy Serina Therapeutics common stock at an exercise price of $1.98 per share. These options vest on the earlier of the day before the next annual meeting or the one-year anniversary of the June 17, 2026 grant date.
How were Serina Therapeutics (SER) Pre-Funded Warrants treated in this insider filing?
Pre-Funded Warrants bought at $2.2499 per warrant under a March 17, 2026 Securities Purchase Agreement automatically converted into common stock once stockholder approval was obtained on June 17, 2026. The warrants carried a $0.0001 exercise price and no expiration date before conversion.